Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
作者： Kimmie Ng , Andrew X. Zhu
DOI: 10.1016/J.CRITREVONC.2007.09.006
关键词:
摘要: Although significant advances have been made in the treatment of metastatic colorectal cancer (CRC), prognosis remains poor, with a 5-year survival less than 10%. Monoclonal antibodies that target epidermal growth factor receptor (EGFR) shown clinical benefit as single agents and combination standard chemotherapy refractory setting, tolerable toxicity. This article will discuss role EGFR pathway pathogenesis CRC, data supporting current use cetuximab panitumumab trials tyrosine kinase inhibitors CRC. Novel strategies targeting to improve efficacy, well ongoing research identifying molecular predictors response anti-EGFR agents, also be reviewed.
elsevier.com
sci-hub.se 参考文章(92)
A. Jimeno, I. Sevilla, C. Gravalos, M. E. Vega, P. Escudero, E. Torre, F. Rivera, M. L. Garcia de Paredes, R. Colomer, H. Cortes-Funes, Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy Journal of Clinical Oncology. ,vol. 23, pp. 3176- 3176 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.3176
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
Takehiko Sasazuki, Senji Shirasawa, Ryo Iwamoto, Ken Yamamoto, Koji Okumura, Miharu Nishioka, Eisuke Mekada, Iwai Baba, Kayako Fukuyama, Toshiyuki Tsunoda, Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Research. ,vol. 60, pp. 6886- 6889 ,(2000)
Mark G. Kris, Howard I. Scher, Vincent A. Miller, Maureen F. Zakowski, Francis M. Sirotnak, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clinical Cancer Research. ,vol. 6, pp. 4885- 4892 ,(2000)
R M Shaheen, S A Ahmad, W Liu, N Reinmuth, Y D Jung, W W Tseng, K E Drazan, C D Bucana, D J Hicklin, L M Ellis, Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors British Journal of Cancer. ,vol. 85, pp. 584- 589 ,(2001) , 10.1054/BJOC.2001.1936
Brian Fendly, Mien Chie Hung, Robert S. Kerbel, Alicia M. Viloria Petit, Patricia Rockwell, Neil Goldstein, Janusz Rak, Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology. ,vol. 151, pp. 1523- 1530 ,(1997)
Paul Perrotte, Hiroki Kuniyasu, Beryl Y. Eve, Daniel J. Hicklin, Keiji Inoue, Colin P. N. Dinney, Robert Radinsky, Takashi Matsumoto, Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research. ,vol. 5, pp. 257- 265 ,(1999)
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
A.M. Kluftinger, B.W. Robinson, N.F. Quenville, R.J. Finley, N.L. Davis, Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surgical Oncology-oxford. ,vol. 1, pp. 97- 105 ,(1992) , 10.1016/0960-7404(92)90062-P
Timothy Kuo, George A. Fisher, Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. Clinical Colorectal Cancer. ,vol. 5, ,(2005) , 10.3816/CCC.2005.S.009